Jason A. Efstathiou - Concepedia

Author

Jason A. Efstathiou

Also Known As

Efstathiou, Jason A., J A Efstathiou, J Efstathiou, J. A. Efstathiou, J. Efstathiou, J.A. Efstathiou, Jason A Efstathiou, Jason A. Efstathiou, Jason Alexander Efstathiou, Jason Efstathiou

649

Publications

21.1K

Citations

H-Index

132

Concepts

All Affiliations

Massachusetts General Hospital Harvard University Brigham and Women's Hospital Dana-Farber Cancer Institute Cedars-Sinai Medical Center

About

Jason A. Efstathiou is an author at Massachusetts General Hospital specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	90	7.4K
2	Health Sciences	13	14	1.3K
3	Education	1	1	64
4	Engineering	1	1	65
5	Management	1	1	64

Jason A. Efstathiou

167

Publications

13.1K

Citations

H-Index

Page 1

	Year	Citations
Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09 Anthony L. Zietman, Kyounghwa Bae, Jerry D. Slater, Journal of Clinical Oncology Trial ComparingRadiation MedicineOncologyClinical OutcomesClinical Radiation Oncology	2010	737
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Journal of the National Comprehensive Cancer Network	2020	619
Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233 Raymond H. Mak, Daniel Hunt, William U. Shipley, Journal of Clinical Oncology	2014	438
Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience Jason A. Efstathiou, Daphna Y. Spiegel, William U. Shipley, European Urology UrologySelective Bladder PreservationSurgical OncologyGenitourinary CancerMedicine	2011	422
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience Nicholas J. Giacalone, William U. Shipley, R.H. Clayman, European Urology Urological ResearchUrologySurgical OncologyVoiding DysfunctionGenitourinary Cancer	2017	390
Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy Rahul D. Tendulkar, Shree Agrawal, Tianming Gao, Journal of Clinical Oncology	2016	376
The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis Hanan Lamlum, Mohammad Ilyas, Andrew Rowan, Nature Medicine Allelic VariantSomatic MutationSomatic VariantGenetic DisorderFamilial Adenomatous Polyposis	1999	370
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Journal of the National Comprehensive Cancer Network Urological ResearchSurgical OncologyUrologyUrologic Cancer EpidemiologyGenitourinary Cancer	2017	276
Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31 Jason A. Efstathiou, Kyounghwa Bae, William U. Shipley, Journal of Clinical Oncology	2008	260
Use of Potentially Curative Therapies for Muscle-invasive Bladder Cancer in the United States: Results from the National Cancer Data Base Phillip J. Gray, Stacey A. Fedewa, William U. Shipley, European Urology Potentially Curative TherapiesUrologySurgical OncologyUrologic Cancer EpidemiologyGenitourinary Cancer	2012	239

Page 1